<SEC-DOCUMENT>0001104659-20-133331.txt : 20201209
<SEC-HEADER>0001104659-20-133331.hdr.sgml : 20201209
<ACCEPTANCE-DATETIME>20201208205714
ACCESSION NUMBER:		0001104659-20-133331
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		4
CONFORMED PERIOD OF REPORT:	20201208
ITEM INFORMATION:		Other Events
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20201209
DATE AS OF CHANGE:		20201208

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Lipocine Inc.
		CENTRAL INDEX KEY:			0001535955
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				990370688
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-36357
		FILM NUMBER:		201376722

	BUSINESS ADDRESS:	
		STREET 1:		675 ARAPEEN DRIVE, SUITE 202
		CITY:			SALT LAKE CITY
		STATE:			X1
		ZIP:			84108
		BUSINESS PHONE:		801 994 7383

	MAIL ADDRESS:	
		STREET 1:		675 ARAPEEN DRIVE, SUITE 202
		CITY:			SALT LAKE CITY
		STATE:			X1
		ZIP:			84108

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	MARATHON BAR CORP
		DATE OF NAME CHANGE:	20111130
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>tm2038073d1_8k.htm
<DESCRIPTION>8-K
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 12pt; margin-bottom: 3pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 2pt solid; border-bottom: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 14pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">UNITED STATES</P>

<P STYLE="font: 14pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">SECURITIES AND EXCHANGE COMMISSION</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">WASHINGTON, D.C. 20549</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 18pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">FORM 8-K</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">CURRENT REPORT</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Pursuant to Section 13 or 15(d) of</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">The Securities Exchange Act of 1934</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Date of Report (Date of Earliest Event Reported):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>December 8, 2020</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><IMG SRC="image_004.jpg" ALT=""><B></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 18pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>LIPOCINE INC.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Exact name of registrant as specified in
its charter)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Commission File No. 001-36357</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 40%; text-align: center"><FONT STYLE="font-size: 10pt">Delaware</FONT></TD>
    <TD STYLE="width: 20%; text-align: center">&nbsp;</TD>
    <TD STYLE="width: 40%; text-align: center"><FONT STYLE="font-size: 10pt">99-0370688</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">(State or other jurisdiction of incorporation)</FONT></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">(IRS Employer Identification Number)</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>675 Arapeen Drive, Suite 202</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Salt Lake City, Utah 84108</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Address of principal executive offices)
(Zip Code)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Registrant&rsquo;s telephone number, including
area code: <B>(801) 994-7383</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Former name or former address, if changed
since last report: <B>Not Applicable</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">______________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Check the appropriate box below if the Form
8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Wingdings">&#168;</FONT></TD><TD STYLE="text-align: justify">Written communications pursuant to Rule 425 under
the Securities Act (17 CFR 230.425)</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Wingdings">&#168;</FONT></TD><TD STYLE="text-align: justify">Soliciting material pursuant to Rule 14a-12 under
the Exchange Act (17 CFR 240.14a-12)</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Wingdings">&#168;</FONT></TD><TD STYLE="text-align: justify">Pre-commencement communications pursuant to Rule 14d-2(b)
under the Exchange Act (17 CFR 240.14d-2(b))</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Wingdings">&#168;</FONT></TD><TD STYLE="text-align: justify">Pre-commencement communications pursuant to Rule 13e-4(c)
under the Exchange Act (17 CFR 240.13e-4(c))</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Indicate by check mark whether the registrant is an emerging
growth company as defined in Rule 405 of the Securities Act of 1933&nbsp;(17 CFR &sect; 230.405) or&nbsp;Rule 12b-2 of the Securities
Exchange Act of 1934&nbsp;(17 CFR &sect; 240.12b-2).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Emerging growth company <FONT STYLE="font-family: Wingdings">&#168;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">If an emerging growth company, indicate by check mark if the
registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards
provided pursuant to&nbsp;Section 13(a) of the Exchange Act. <FONT STYLE="font-family: Wingdings">&#168;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">Securities
registered pursuant to&nbsp;<U>Section 12(b)</U>&nbsp;of the Act</FONT>:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="border-bottom: rgb(204,204,204) 1pt solid; width: 40%">&nbsp;</TD>
    <TD STYLE="border-bottom: rgb(204,204,204) 1pt solid; width: 20%">&nbsp;</TD>
    <TD STYLE="border-bottom: rgb(204,204,204) 1pt solid; width: 40%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="border-right: #CCCCCC 1pt solid; border-left: #CCCCCC 1pt solid; border-bottom: Black 1pt solid; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title of each class</FONT></TD>
    <TD STYLE="border-right: #CCCCCC 1pt solid; border-bottom: Black 1pt solid; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Trading Symbol(s)</FONT></TD>
    <TD STYLE="border-right: #CCCCCC 1pt solid; border-bottom: Black 1pt solid; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name of each exchange on which registered</FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="border-right: #CCCCCC 1pt solid; border-bottom: #CCCCCC 1pt solid; border-left: #CCCCCC 1pt solid; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Common Stock, par value $0.0001 per share</FONT></TD>
    <TD STYLE="border-right: #CCCCCC 1pt solid; border-bottom: #CCCCCC 1pt solid; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">LPCN</FONT></TD>
    <TD STYLE="border-right: #CCCCCC 1pt solid; border-bottom: #CCCCCC 1pt solid; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The NASDAQ Stock Market LLC</FONT></TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 3pt; margin-bottom: 12pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; border-bottom: Black 2pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 1in"><B>Item&nbsp;8.01</B></TD>
    <TD><B>Other Events</B></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">On December 8, 2020, the Company issued
a press release announcing deletion of unauthorized changes to the Company&rsquo;s website. The press release is filed as Exhibit
99.1 and is incorporated herein by reference.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">Additionally on December 8, 2020, the
Company issued a press release announcing the tentative approval of TLANDO&trade;. The press release is filed as Exhibit 99.2 and
is incorporated herein by reference.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 1in">Item 9.01</TD><TD>Financial Statements and Exhibits.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">(d)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Exhibits</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The following exhibits are filed with this report:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: Black 1pt solid; width: 19%; padding-bottom: 12pt"><FONT STYLE="font-size: 10pt"><U>Exhibit No.&#9;</U></FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; width: 81%; padding-bottom: 12pt"><FONT STYLE="font-size: 10pt"><U>Description</U></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-bottom: 6pt"><A HREF="tm2038073d1_ex99-1.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">99.1</FONT></A></TD>
    <TD STYLE="padding-bottom: 6pt"><A HREF="tm2038073d1_ex99-1.htm" STYLE="-sec-extract: exhibit">Press Release announcing Deletion
of Unauthorized Changes to Company&rsquo;s Website</A></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><A HREF="tm2038073d1_ex99-2.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">99.2</FONT></A></TD>
    <TD><A HREF="tm2038073d1_ex99-2.htm" STYLE="-sec-extract: exhibit">Press Release announcing Tentative Approval of TLANDO</A></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 85.5pt">&nbsp;</P>


<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">SIGNATURES</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.75in">Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2"><FONT STYLE="font-size: 10pt">LIPOCINE INC.</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 8%">&nbsp;</TD>
    <TD STYLE="width: 32%">&nbsp;</TD>
    <TD STYLE="width: 11%">&nbsp;</TD>
    <TD STYLE="width: 6%">&nbsp;</TD>
    <TD STYLE="width: 43%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">Date:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid"><FONT STYLE="font-size: 10pt">December 8, 2020</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid"><FONT STYLE="font-size: 10pt">/s/ Mahesh V. Patel</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">Mahesh V. Patel</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">President and Chief Executive Officer</FONT></TD></TR>
</TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="margin-top: 0; margin-bottom: 0"></P>

<!-- Field: Page; Sequence: 3; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>tm2038073d1_ex99-1.htm
<DESCRIPTION>EXHIBIT 99.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right; background-color: white">Exhibit 99.1</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><IMG SRC="image_004.jpg" ALT=""><B></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><B>Lipocine Announces
Deletion of Unauthorized Changes to Company&rsquo;s Website</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>SALT LAKE CITY, December 8, 2020 &ndash; </B>Lipocine Inc.
(NASDAQ: LPCN), a clinical-stage biopharmaceutical company focused on metabolic and endocrine disorders, today announced that an
independent contractor posted on Lipocine&rsquo;s website (www.lipocine.com), without authorization from Lipocine, statements suggesting
that TLANDO was approved by the U.S. Food and Drug Administration (&ldquo;FDA&rdquo;). TLANDO has not received final approval from
the FDA. Upon learning of the unauthorized posting to its website, Lipocine deleted the incorrect posting.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><B>For further information: </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">Morgan Brown</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">Executive Vice President &amp; Chief
Financial Officer</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">Phone: (801) 994-7383</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><U>mb@lipocine.com</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">Investors</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">Hans Vitzthum</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">Phone: (617) 535-7743</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><U>hans@lifesciadvisors.com</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><B>&nbsp;</B></P>


<!-- Field: Page; Sequence: 1; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.2
<SEQUENCE>3
<FILENAME>tm2038073d1_ex99-2.htm
<DESCRIPTION>EXHIBIT 99.2
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><B>Exhibit 99.2</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><IMG SRC="image_004.jpg" ALT=""><B></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><B>Lipocine Announces
Tentative Approval of TLANDO&trade;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>SALT LAKE CITY, December 8, 2020 &ndash; </B>Lipocine Inc.
(NASDAQ: LPCN), a clinical-stage biopharmaceutical company focused on metabolic and endocrine disorders, today announced that the
U.S. Food and Drug Administration (&ldquo;FDA&rdquo;) has granted tentative approval to TLANDO, its oral testosterone product for
testosterone replacement therapy (&quot;TRT&quot;) in adult males indicated for conditions associated with a deficiency or absence
of endogenous testosterone<FONT STYLE="font-family: Times New Roman, Times, Serif; color: #3E4C4D; background-color: white">: </FONT>primary
hypogonadism (congenital or acquired) and hypogonadotropic hypogonadism (congenital or acquired). In granting tentative approval,
the FDA has concluded that TLANDO has met all required quality, safety and efficacy standards necessary for approval, but TLANDO
has not received final approval and is not eligible for final approval and marketing in the U.S. until the expiration of the exclusivity
period previously granted to Clarus Therapeutics, Inc. with respect to Jatenzo&reg;, which expires on March 27, 2022. Lipocine
is currently reviewing FDA&rsquo;s tentative approval of TLANDO and remains committed to taking appropriate actions with the goal
of receiving final approval to permit the launch of TLANDO. The FDA has also required Lipocine to conduct certain post-marketing
studies to (i) assess patient understanding of key risks relating to TLANDO and (ii) evaluate development of adrenal insufficiency
with chronic TLANDO therapy.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&ldquo;We are pleased to have received this tentative approval
for TLANDO. The tentative approval is supported by a strong clinical and CMC data package. This is an important step towards getting
our oral TRT no-titration option to patients. We are committed to working towards obtaining final approval of TLANDO,&rdquo; said
Dr. Mahesh Patel, Chairman, President and Chief Executive Officer of Lipocine. Dr. Patel further stated, &ldquo;We believe that
TLANDO represents a differentiated TRT for treating hypogonadism in men, with the potential to both improve patient compliance
and overcome inadvertent testosterone transference and pulmonary oil micro-embolism risks, effects often associated with existing
non-oral treatments.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><B>About Lipocine</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">Lipocine Inc. is a clinical-stage biopharmaceutical
company focused on metabolic and endocrine disorders using its proprietary drug delivery technologies. Lipocine's clinical development
pipeline includes LPCN 1144, TLANDO XR, LPCN 1148 and LPCN 1107. TLANDO, a novel oral prodrug of testosterone containing testosterone
undecanoate, has received tentative approval from the FDA for conditions associated with a deficiency of endogenous testosterone,
also known as hypogonadism, in adult males. LPCN 1144, an oral product of bioidentical testosterone, recently completed a proof-of-concept
clinical study demonstrating the potential utility in the treatment of non-cirrhotic NASH.&nbsp; LPCN 1144 is currently being studied
in a Phase 2 clinical study.&nbsp; TLANDO XR, a novel oral prodrug of testosterone, originated and is being developed by Lipocine
as a next-generation oral testosterone product with potential for once-daily dosing. In a phase 2 clinical evaluation when administered
as once daily or twice daily TLANDO XR met the typical primary and secondary end points. LPCN 1148 is an oral prodrug of bioidentical
testosterone targeted for the treatment of cirrhosis. LPCN 1107 is potentially the first oral hydroxyprogesterone caproate product
candidate indicated for the prevention of recurrent preterm birth and has been granted orphan drug designation by the FDA. For
more information, please visit&nbsp;www.lipocine.com.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><B>Forward-Looking Statements<BR>
</B>This release contains &quot;forward-looking statements&quot; that are made pursuant to the safe harbor provisions of the Private
Securities Litigation Reform Act of 1995 and include statements that are not historical facts regarding the timing and receipt
of final approval of TLANDO, the expiration of exclusivity rights of third party products, the timing of completion of clinical
trials and other studies, the regulatory approval process of our product candidates, the potential uses and benefits of our product
candidates, and our product development efforts. Investors are cautioned that all such forward-looking statements involve risks
and uncertainties, including, without limitation, the risks that the FDA will not grant final approval for TLANDO, that the FDA
will not approve any of our products, risks related to exclusivity granted by the FDA to competing products, risks related to our
products, expected product benefits not being realized, clinical and regulatory expectations and plans not being realized, new
regulatory developments and requirements, risks related to the FDA approval process including the receipt of regulatory approvals,
the results and timing of clinical trials, patient acceptance of Lipocine's products, the manufacturing and commercialization of
Lipocine's products, and other risks detailed in Lipocine's filings with the SEC, including, without limitation, its Form 10-K
and other reports on Forms 8-K and 10-Q, all of which can be obtained on the SEC website at&nbsp;www.sec.gov. Lipocine assumes
no obligation to update or revise publicly any forward-looking statements contained in this release, except as required by law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><B>For further information: </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">Morgan Brown</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">Executive Vice President &amp; Chief
Financial Officer</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">Phone: (801) 994-7383</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><U>mb@lipocine.com</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">Investors</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">Hans Vitzthum</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">Phone: (617) 535-7743</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><U>hans@lifesciadvisors.com</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"></P>

<!-- Field: Page; Sequence: 2; Options: Last -->
    <DIV STYLE="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>


</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>image_004.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_004.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" !* 0(# 2(  A$! Q$!_\0
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MV%[_ %/Y&L"&V^*?B(?:5FU*%&Y!\\6H_!05_E7<^ /AU:>'K2+4-2A2;5G
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M_P!&1U[S7S)X&\5IX/UN;4)+1KH26S0;%?9C+*V<X/\ =_6O0?\ A>5M_P!
M&7_P)'_Q- 'K5>&?&[_D9M/_ .O/_P!G:MG_ (7E;?\ 0!E_\"1_\36#\8YQ
M=:UI%P%VB73U?;G.,LQQ0!O?&7_D6=#_ .NA_P#0!7>>"?\ D1]$_P"O./\
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M1^&K'6]+0G4+=IUDA!P+J+SG)0_[0ZJ>Q^M:7P^N$N]&U"YC#!)=3N)%##!
M+9&1V-=8  , 8I  .@ H<[IBA1Y6FGL<:-/O;[QMKOV/5[C3]D=MN$4:/ORK
M8SN!Z<]/6K'AFVN+3Q3X@AN;V2]E"6I,TB*I/ROQA0!75X&<XHP,YQ1SZ6&J
M*33\VSDO%S7FJ7EGH&G1P3.<7=VDTA1#$C#:I(!^\W_H)J'19-2T?Q5/;ZK!
M;01:P3-"+:5G03HHWC) P67G_@)KL\#.<<T8!QQTHYM+ Z5Y<]]3FO%<:2WW
MAV.15='U(*RL,@@Q29!KG?$$5SHC:5HSB273VU2VDL9CD^6 XS"Q]LY4GMQV
MKT? ...E(0#U -"G84Z/-=WW,CQ597&H^%M2M+1=T\L)"+G&[OM_'I^-4X_&
M?A_["O\ I*K,%"_8=A\X-C[@CQDGMTQ724W8F_?M7=_>QS235K,N47S<T616
M1)L8";;[+E ?(X_=\?=XXX]JP_ __(M_]O=S_P"CGKHZ  .@I7TL/EU3['&'
M25U;Q%XD5)3!>0S6TEK<J.8I!",'W!Z$=P:B\,7MQ?>.]7:\MC;W<=E#%/&>
M@<,W*GNIX(/H:[C SG%)@9)P,GO5<^EC/V.J:?6_Y_YG,:U,FD^++'6+U&_L
M\6DELTX4L('+*0S8Z @8S^=8]QKTC^(M-6R\0+J=O/?*KQ):QF.%&R0/, ^]
MQ@<YX)KT"FJB*H"JH [ 4*2'*DV]'UN.K+\2?\BMJ_\ UY3?^@&M2BI6C-9*
MZ:."N=%U4>")ISXDO&A&FLY@\B':5\O.W.W.,<>M=?HW_("T_P#Z]H__ $$5
M>P,8QQ13<KHSA24'==CR[3=1M;9]1CE\9MI;_P!H7)-L$B./WK<_,I/->BV-
MY;RZ3#=)>K<0"+<;G@!P!RQQP.A-63%&3DQJ3]*<  ,  #TIRDF*E3<.OY_Y
MGFXTS7_$=IJ>H0V>G^5JQ5K>6>=TDAC0_NB $..F[KSFNT\.:JVKZ)#<3+LN
MDS#<Q]TE4X<?F,_0BM6C '042E=6"G2Y'>_J<3I7B+1]'UGQ%!J.HP6TKZB7
M5)&P2/+09_0UV-K=07MK'<VTJRP2KN1U.0P]13S&C')12?4BG  # &!2DTRH
M1E'1O0Y[PE_JM8_["US_ .A5%XY1Y-%M(XY6B=M1M@LB@$H3(,$ \<>]=-@#
MH*" >HHYO>N'L_W?(<)XBTG4K.#3Y;K7[J]C&I6H\F2&)03YJ\Y50:[N@@'J
1**'*Z"%-1;:ZA1114FA__]D!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
